Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 22, 2022 07:12 ET | Source: Arvinas Inc.

Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)

ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer Median progression free survival of 3.7 months in all patients and 5.7...
November 08, 2022 07:00 ET | Source: Arvinas Inc.

Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update

– On track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer – – Enrolling multiple clinical trials and initiating enrollment...
November 01, 2022 16:00 ET | Source: Arvinas Inc.

Arvinas to Present at Upcoming Conferences

NEW HAVEN, Conn., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
October 27, 2022 07:00 ET | Source: Arvinas Inc.

Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award

NEW HAVEN, Conn., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation (TPD),...
October 03, 2022 07:00 ET | Source: Arvinas Inc.

Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

NEW HAVEN, Conn., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
September 30, 2022 09:00 ET | Source: Arvinas Inc.

Arvinas Gives Back to Local Greater New Haven Community

NEW HAVEN, Conn., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
September 26, 2022 07:00 ET | Source: Arvinas Inc.

Arvinas to Present at Bank of America Securities Precision Oncology Conference

NEW HAVEN, Conn., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
August 31, 2022 07:00 ET | Source: Arvinas Inc.

Arvinas to Present at Upcoming Investor Conferences

NEW HAVEN, Conn., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
August 18, 2022 16:01 ET | Source: Arvinas Inc.

Arvinas Announces Changes to its Board of Directors

NEW HAVEN, Conn., Aug. 18, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
August 15, 2022 07:00 ET | Source: Arvinas Inc.

Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

NEW HAVEN, Conn., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...